107469-64-7

Basic information

• Product Name: ethyl 2-amino-2-(2-(2-phenylacetyl)hydrazono)acetate
• Synonyms: ethyl 2-amino-2-(2-(2-phenylacetyl)hydrazono)acetate
• CAS NO: 107469-64-7
• Molecular Weight: 249.269
• Mol File: 107469-64-7.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: ethyl 2-amino-2-(2-(2-phenylacetyl)hydrazono)acetate(CAS DataBase Reference)
• NIST Chemistry Reference: ethyl 2-amino-2-(2-(2-phenylacetyl)hydrazono)acetate(107469-64-7)
• EPA Substance Registry System: ethyl 2-amino-2-(2-(2-phenylacetyl)hydrazono)acetate(107469-64-7)

Safety Data

• Hazardous Substances Data: 107469-64-7(Hazardous Substances Data)

Upstream product

• 112032-60-7 Amino-(phenylacetyl-hydrazono)-acetic acid ethyl ester; hydrochloride 
• 16982-21-1 ethyl 2-amino-2-thioxoacetate 
• 937-39-3 2-phenylacetylhydrazine 
• 103-80-0 phenylacetyl chloride 
• 816-27-3 ethyl 2-ethoxy-2-iminoacetate 
• 55149-83-2 ethyl 2-ethoxy-2-iminoacetate hydrochloride 

Downstream Products

• 107451-25-2 C₁₀H₇N₃O₂^(2-)*2K⁽¹⁺⁾ 
• 112032-73-2 2-Amino-2-(phenylacetyl-hydrazono)-acetamide 
• 112032-64-1 Amino-(phenylacetyl-hydrazono)-acetic acid 
• 112032-82-3 Amino-(phenylacetyl-hydrazono)-acetic acid hydrazide 
• 112032-91-4 Phenyl-acetic acid [1-amino-1-(5-amino-[1,3,4]oxadiazol-2-yl)-meth-(Z)-ylidene]-hydrazide 
• 1622849-43-7 (S)-5-benzyl-N-(7,9-difluoro-2-oxo-2,3,4,5-tetrahydro-1H-benzo[b]azepin-3-yl)-4H-1,2,4-triazole-3-carboxamide 

Relevant articles and documents

Expanding the chemical space of 3(5)-functionalized 1,2,4-triazoles

[Figure not available: see fulltext.] An efficient approach to the gram-scale synthesis of 3(5)-substituted, 1,3- and 1,5-disubstituted 1,2,4-triazole-derived building blocks is described. The key synthetic precursors – 1,2,4-triazole-3(5)-carboxylates (2

HETEROCYCLIC AMIDES AS KINASE INHIBITORS

Disclosed is a combination of a RIP1 kinase inhibitor compound and at least one other therapeutically active agent for use in the treatment of a RIP1 kinase mediated disease or disorder; particularly disclosed is a combination of a RIP1 kinase inhibitor compound and at least one other therapeutically active agent, wherein the at least one other therapeutically active agent is an immuno-modulator, for use in the treatment of cancer.

HETEROCYCLIC AMIDES AS KINASE INHIBITORS

Disclosed are compounds having the formula (I) wherein X, Y, Z1, Z2, Z3, Z4, R5, RA, m, A. L, and B are as defined herein, and methods of making and using the same.